Generic versions of key diabetic drug in market double in a month

Post patent expiry, numerous Indian companies launched generic versions of Empagliflozin. The market witnessed a surge in brands and players in April. This makes diabetes drugs more affordable for Indian patients. Prices have dropped significantly, increasing access. Doctors are optimistic about the future. More patent expirations will further benefit patients. Semaglutide's upcoming patent expiry could revolutionize diabetes treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/I3WMt5d
via IFTTT